The effects of argatroban on thrombin generation and hemostatic activation in vitro

Kenichi A. Tanaka, Fania Szlam, Nobuyuki Katori, Nobukazu Sato, J. David Vega, Jerrold H. Levy

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

We evaluated argatroban, a direct thrombin inhibitor, as a heparin adjunct for anticoagulation. Platelet-poor plasma (PPP) was isolated from blood collected from 12 volunteers. Thrombin generation measurements were performed in donor PPP that was mixed with antithrombin (AT)-poor plasma to yield AT levels of 0%, 20%, 60%, and 100%. Effects of argatroban (0-1.0 μg/ mL), heparin (0.25 U/mL), or the combination of argatroban (0.5 μg/mL) and heparin were also studied. The addition of increasing concentrations of argatroban, heparin, or both to donor PPP (AT level ∼100%) caused progressive decreases in the lag time and peak formation of thrombin generation. Heparin (0.25 U/mL) at small AT concentrations had a minimal effect on lag time or peak thrombin formation; its effectiveness of inhibiting thrombin was directly correlated with the concentration of AT. Argatroban at 0.5 μg/mL, was effective in decreasing thrombin formation at both low and normal AT levels, but it was most effective when combined with heparin. Additionally, blood samples were obtained from 47 cardiac surgical patients, and the interaction of heparin (>1.5 U/mL) and AT or argatroban on clot formation was evaluated with kaolin activated clotting times (ACTs). Significant increases of ACTs at all heparin levels were observed with the addition of argatroban (0.125 and 0.25 μg/mL). The addition of AT (0.2 U/mL) to heparinized blood samples further prolonged ACTs. In summary, we showed that argatroban, unlike heparin, could effectively reduce thrombin generation regardless of AT levels and could prolong ACTs in vitro at clinically used concentrations.

Original languageEnglish
Pages (from-to)1283-1289
Number of pages7
JournalAnesthesia and Analgesia
Volume99
Issue number5
DOIs
Publication statusPublished - 2004 Nov
Externally publishedYes

Fingerprint

Antithrombins
Hemostatics
Thrombin
Heparin
Blood Platelets
In Vitro Techniques
argatroban
Tissue Donors
Kaolin
Volunteers

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine

Cite this

Tanaka, K. A., Szlam, F., Katori, N., Sato, N., Vega, J. D., & Levy, J. H. (2004). The effects of argatroban on thrombin generation and hemostatic activation in vitro. Anesthesia and Analgesia, 99(5), 1283-1289. https://doi.org/10.1213/01.ANE.0000134685.75813.EB

The effects of argatroban on thrombin generation and hemostatic activation in vitro. / Tanaka, Kenichi A.; Szlam, Fania; Katori, Nobuyuki; Sato, Nobukazu; Vega, J. David; Levy, Jerrold H.

In: Anesthesia and Analgesia, Vol. 99, No. 5, 11.2004, p. 1283-1289.

Research output: Contribution to journalArticle

Tanaka, KA, Szlam, F, Katori, N, Sato, N, Vega, JD & Levy, JH 2004, 'The effects of argatroban on thrombin generation and hemostatic activation in vitro', Anesthesia and Analgesia, vol. 99, no. 5, pp. 1283-1289. https://doi.org/10.1213/01.ANE.0000134685.75813.EB
Tanaka, Kenichi A. ; Szlam, Fania ; Katori, Nobuyuki ; Sato, Nobukazu ; Vega, J. David ; Levy, Jerrold H. / The effects of argatroban on thrombin generation and hemostatic activation in vitro. In: Anesthesia and Analgesia. 2004 ; Vol. 99, No. 5. pp. 1283-1289.
@article{bea42c3171d3482a9e1e3b73b9bf691a,
title = "The effects of argatroban on thrombin generation and hemostatic activation in vitro",
abstract = "We evaluated argatroban, a direct thrombin inhibitor, as a heparin adjunct for anticoagulation. Platelet-poor plasma (PPP) was isolated from blood collected from 12 volunteers. Thrombin generation measurements were performed in donor PPP that was mixed with antithrombin (AT)-poor plasma to yield AT levels of 0{\%}, 20{\%}, 60{\%}, and 100{\%}. Effects of argatroban (0-1.0 μg/ mL), heparin (0.25 U/mL), or the combination of argatroban (0.5 μg/mL) and heparin were also studied. The addition of increasing concentrations of argatroban, heparin, or both to donor PPP (AT level ∼100{\%}) caused progressive decreases in the lag time and peak formation of thrombin generation. Heparin (0.25 U/mL) at small AT concentrations had a minimal effect on lag time or peak thrombin formation; its effectiveness of inhibiting thrombin was directly correlated with the concentration of AT. Argatroban at 0.5 μg/mL, was effective in decreasing thrombin formation at both low and normal AT levels, but it was most effective when combined with heparin. Additionally, blood samples were obtained from 47 cardiac surgical patients, and the interaction of heparin (>1.5 U/mL) and AT or argatroban on clot formation was evaluated with kaolin activated clotting times (ACTs). Significant increases of ACTs at all heparin levels were observed with the addition of argatroban (0.125 and 0.25 μg/mL). The addition of AT (0.2 U/mL) to heparinized blood samples further prolonged ACTs. In summary, we showed that argatroban, unlike heparin, could effectively reduce thrombin generation regardless of AT levels and could prolong ACTs in vitro at clinically used concentrations.",
author = "Tanaka, {Kenichi A.} and Fania Szlam and Nobuyuki Katori and Nobukazu Sato and Vega, {J. David} and Levy, {Jerrold H.}",
year = "2004",
month = "11",
doi = "10.1213/01.ANE.0000134685.75813.EB",
language = "English",
volume = "99",
pages = "1283--1289",
journal = "Anesthesia and Analgesia",
issn = "0003-2999",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - The effects of argatroban on thrombin generation and hemostatic activation in vitro

AU - Tanaka, Kenichi A.

AU - Szlam, Fania

AU - Katori, Nobuyuki

AU - Sato, Nobukazu

AU - Vega, J. David

AU - Levy, Jerrold H.

PY - 2004/11

Y1 - 2004/11

N2 - We evaluated argatroban, a direct thrombin inhibitor, as a heparin adjunct for anticoagulation. Platelet-poor plasma (PPP) was isolated from blood collected from 12 volunteers. Thrombin generation measurements were performed in donor PPP that was mixed with antithrombin (AT)-poor plasma to yield AT levels of 0%, 20%, 60%, and 100%. Effects of argatroban (0-1.0 μg/ mL), heparin (0.25 U/mL), or the combination of argatroban (0.5 μg/mL) and heparin were also studied. The addition of increasing concentrations of argatroban, heparin, or both to donor PPP (AT level ∼100%) caused progressive decreases in the lag time and peak formation of thrombin generation. Heparin (0.25 U/mL) at small AT concentrations had a minimal effect on lag time or peak thrombin formation; its effectiveness of inhibiting thrombin was directly correlated with the concentration of AT. Argatroban at 0.5 μg/mL, was effective in decreasing thrombin formation at both low and normal AT levels, but it was most effective when combined with heparin. Additionally, blood samples were obtained from 47 cardiac surgical patients, and the interaction of heparin (>1.5 U/mL) and AT or argatroban on clot formation was evaluated with kaolin activated clotting times (ACTs). Significant increases of ACTs at all heparin levels were observed with the addition of argatroban (0.125 and 0.25 μg/mL). The addition of AT (0.2 U/mL) to heparinized blood samples further prolonged ACTs. In summary, we showed that argatroban, unlike heparin, could effectively reduce thrombin generation regardless of AT levels and could prolong ACTs in vitro at clinically used concentrations.

AB - We evaluated argatroban, a direct thrombin inhibitor, as a heparin adjunct for anticoagulation. Platelet-poor plasma (PPP) was isolated from blood collected from 12 volunteers. Thrombin generation measurements were performed in donor PPP that was mixed with antithrombin (AT)-poor plasma to yield AT levels of 0%, 20%, 60%, and 100%. Effects of argatroban (0-1.0 μg/ mL), heparin (0.25 U/mL), or the combination of argatroban (0.5 μg/mL) and heparin were also studied. The addition of increasing concentrations of argatroban, heparin, or both to donor PPP (AT level ∼100%) caused progressive decreases in the lag time and peak formation of thrombin generation. Heparin (0.25 U/mL) at small AT concentrations had a minimal effect on lag time or peak thrombin formation; its effectiveness of inhibiting thrombin was directly correlated with the concentration of AT. Argatroban at 0.5 μg/mL, was effective in decreasing thrombin formation at both low and normal AT levels, but it was most effective when combined with heparin. Additionally, blood samples were obtained from 47 cardiac surgical patients, and the interaction of heparin (>1.5 U/mL) and AT or argatroban on clot formation was evaluated with kaolin activated clotting times (ACTs). Significant increases of ACTs at all heparin levels were observed with the addition of argatroban (0.125 and 0.25 μg/mL). The addition of AT (0.2 U/mL) to heparinized blood samples further prolonged ACTs. In summary, we showed that argatroban, unlike heparin, could effectively reduce thrombin generation regardless of AT levels and could prolong ACTs in vitro at clinically used concentrations.

UR - http://www.scopus.com/inward/record.url?scp=6444239394&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=6444239394&partnerID=8YFLogxK

U2 - 10.1213/01.ANE.0000134685.75813.EB

DO - 10.1213/01.ANE.0000134685.75813.EB

M3 - Article

C2 - 15502018

AN - SCOPUS:6444239394

VL - 99

SP - 1283

EP - 1289

JO - Anesthesia and Analgesia

JF - Anesthesia and Analgesia

SN - 0003-2999

IS - 5

ER -